207 related articles for article (PubMed ID: 25170759)
1. Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.
Cao Y; Roth M; Piperdi S; Montoya K; Sowers R; Rao P; Geller D; Houghton P; Kolb EA; Gill J; Gorlick R
PLoS One; 2014; 9(8):e106249. PubMed ID: 25170759
[TBL] [Abstract][Full Text] [Related]
2. Assessment of GSK1904529A as a promising anti-osteosarcoma agent.
Fei HD; Yuan Q; Mao L; Chen FL; Cui ZH; Tao S; Ji F
Oncotarget; 2017 Jul; 8(30):49646-49654. PubMed ID: 28572530
[TBL] [Abstract][Full Text] [Related]
3. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
4. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.
Kang Z; Yu Y; Zhu YJ; Davis S; Walker R; Meltzer PS; Helman LJ; Cao L
Oncogene; 2014 Dec; 33(50):5697-705. PubMed ID: 24292683
[TBL] [Abstract][Full Text] [Related]
6. Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.
Nomura M; Rainusso N; Lee YC; Dawson B; Coarfa C; Han R; Larson JL; Shuck R; Kurenbekova L; Yustein JT
J Natl Cancer Inst; 2019 Nov; 111(11):1216-1227. PubMed ID: 30793158
[TBL] [Abstract][Full Text] [Related]
7. Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor.
Raile K; Höflich A; Kessler U; Yang Y; Pfuender M; Blum WF; Kolb H; Schwarz HP; Kiess W
J Cell Physiol; 1994 Jun; 159(3):531-41. PubMed ID: 8188767
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of microRNA-7 contributes to inhibition of the growth and metastasis of osteosarcoma cells through the inhibition of IGF1R.
Zhang Z; Zhao M; Wang G
J Cell Physiol; 2019 Dec; 234(12):22195-22206. PubMed ID: 31102265
[TBL] [Abstract][Full Text] [Related]
9. Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody.
Kim JG; Kang MJ; Yoon YK; Kim HP; Park J; Song SH; Han SW; Park JW; Kang GH; Kang KW; Oh DY; Im SA; Bang YJ; Yi EC; Kim TY
PLoS One; 2012; 7(3):e33322. PubMed ID: 22438913
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.
Dziadziuszko R; Merrick DT; Witta SE; Mendoza AD; Szostakiewicz B; Szymanowska A; Rzyman W; Dziadziuszko K; Jassem J; Bunn PA; Varella-Garcia M; Hirsch FR
J Clin Oncol; 2010 May; 28(13):2174-80. PubMed ID: 20351332
[TBL] [Abstract][Full Text] [Related]
12. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines.
Luk F; Yu Y; Walsh WR; Yang JL
Cancer Invest; 2011 Oct; 29(8):521-32. PubMed ID: 21843050
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of lncRNA SNHG12 reversed IGF1R-induced osteosarcoma metastasis and proliferation by targeting miR-195-5p.
Xu N; Xu J; Zuo Z; Liu Y; Yan F; Han C
Gene; 2020 Feb; 726():144145. PubMed ID: 31743769
[TBL] [Abstract][Full Text] [Related]
14. The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor.
Chen KT; Hour MJ; Tsai SC; Chung JG; Kuo SC; Lu CC; Chiu YJ; Chuang YH; Yang JS
Int J Oncol; 2011 Sep; 39(3):611-9. PubMed ID: 21667022
[TBL] [Abstract][Full Text] [Related]
15. IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer.
Neuzillet Y; Chapeaublanc E; Krucker C; De Koning L; Lebret T; Radvanyi F; Bernard-Pierrot I
BMC Cancer; 2017 Sep; 17(1):636. PubMed ID: 28882129
[TBL] [Abstract][Full Text] [Related]
16. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
17. Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines.
Li J; Hu XF; Loveland BE; Xing PX
Exp Hematol; 2009 Nov; 37(11):1284-94. PubMed ID: 19703513
[TBL] [Abstract][Full Text] [Related]
18. Amplification of the insulin-like growth factor 1 receptor gene is a rare event in adrenocortical adenocarcinomas: searching for potential mechanisms of overexpression.
Ribeiro TC; Jorge AA; Almeida MQ; Mariani BM; Nishi MY; Mendonca BB; Fragoso MC; Latronico AC
Biomed Res Int; 2014; 2014():936031. PubMed ID: 25110710
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
20. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
